Intra cellular therapies inc news
WebApr 6, 2024 · As of April 06, 2024, 4:00 PM CST, Intra-Cellular Therapies Inc’s stock price was $59.30. Intra-Cellular Therapies Inc is up 4.94% from its previous closing price of $56.51. During the last market session, Intra-Cellular Therapies Inc’s stock traded between $55.26 and $56.92. Currently, there are 94.76 million shares of Intra-Cellular ... WebIntra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update. Full year 2024 total revenues of $250.3 million, compared to $83.8 million in 2024 CAPLYTA fourth quarter 2024 net product sales grew to $87.4 million, a 243% increase over the same period in 2024 and a 22% sequential increase over the …
Intra cellular therapies inc news
Did you know?
WebDec 18, 2015 · Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in ... WebJan 9, 2024 · Events and Presentations Intra-Cellular Therapies Inc. Events. 22nd Annual Needham Virtual Healthcare Conference. April 18, 2024 at 11:45 AM EDT. Listen to Webcast.
WebApr 6, 2024 · A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. WebJan 7, 2024 · NEW YORK, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the completion of its previously announced underwritten public offering of …
WebApr 12, 2024 · Intra-Cellular Therapies, Inc. has a 1-year low of $42.01 and a 1-year high of $65.98. The firm has a market capitalization of $5.59 billion, a price-to-earnings ratio of -21.58 and a beta of 1.15. WebMar 29, 2024 · See our latest analysis for Intra-Cellular Therapies. Consensus from 13 of the American Pharmaceuticals analysts is that Intra-Cellular Therapies is on the verge of breakeven. They anticipate the ...
WebApr 10, 2024 · Intra-Cellular Therapies Inc. (NASDAQ: ITCI)’s stock price has increased by 4.94 compared to its previous closing price of 56.51. However, the company has seen a gain of 5.80% in its stock price over the last five trading days. The Wall Street Journal reported on 12/20/21 that Pandemic Trades Roar Back: What to Watch in the Stock …
WebJan 3, 2024 · Press Releases. Year. 2024. March 1, 2024. Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update. PDF Version. February 14, 2024. Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. PDF Version. neoprene gasket replace wax ring gasketWebNEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ... it security - echonet mobileWebApr 14, 2024 · Knights of Columbus Asset Advisors LLC raised its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Rating) by 104.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.The firm owned 23,506 shares of the biopharmaceutical company's stock after acquiring an … neoprene fork dust covers